: A recent 2025 report noted smooth embarkation despite a previous norovirus outbreak on a prior sailing, confirming the crew's effective disinfection protocols . Finance: NewAmsterdam Pharma (NAMS)

The company's full-year 2025 financial report, released in , shows a focus on clinical development .

: Reported $728.9 million in cash and equivalents as of December 31, 2025, a decrease from the previous year due to R&D spending .

: Ongoing heavy investment in the development of obicetrapib . Finance: New Amsterdam Invest N.V.

: Reported earnings of €0.47 per ordinary share . Entertainment: NBC's "New Amsterdam" TV Series